CareLit · DOI-Nachweis · Aktuelle Neurologie
Tegwondo – development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent gliomas
DOI 10.1055/s-0028-1086680
Bibliografische Angaben
Nachweis in CareLit
Autor:innenH Strik, J.H Buhk, C Bock, M Nitsche, A.L Hoffmann, A Wrede, C Marosi, U Kaiser, M Christmann, B Kaina
ZeitschriftAktuelle Neurologie
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: We report on activity and feasibility of a rechallenge of recurrent gliomas with temozolomide (TMZ) in a dose-dense 21/28-day regimen and development of a novel 5/7-day schedule. Methods: 40 recurrent glioma-patients received TMZ 100mg/m2 with individual dose adaptation: 21 pts. received 148 cycles day 1–21/28 (18 WHO IV [GBM], 3 WHO III). GBM-pts. had a mean age of 54.4y, median KPS was 60%. Patients wi…
Zitieren
Zitierempfehlung
H Strik, J.H Buhk, C Bock, M Nitsche, A.L Hoffmann, A Wrede, C Marosi, U Kaiser, M Christmann, B Kaina (2008) Tegwondo – development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent gliomas. Aktuelle Neurologie (09). https://doi.org/10.1055/s-0028-1086680
Mit CareLit weiterarbeiten